A First-in-Human Phase I Study of ATG-031 in Patients with Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas
This is a first-in-human study to learn more about the study drug ATG-031 in patients with advanced solid tumors or B-cell Non-Hodgkin Lymphomas.
Why this Research Matters
This is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-cell Non-Hodgkin Lymphomas. The study design includes a Dose Escalation Phase and a Dose Expansion Phase.
Who can Participate
Adult
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. Visit ClinicalTrials.gov to learn more about this study.
Study ID
Protocol Number: 23-1892
More information available at ClinicalTrials.gov: NCT06028373
Meet the Team
Principal Investigator